Park Sung Wook, Kim Jin Hyoung, Kim Ko-Eun, Jeong Moon Hee, Park Hyunsung, Park Bongju, Suh Young-Ger, Park Woo Jin, Kim Jeong Hun
Fight against Angiogenesis-Related Blindness Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, Korea; Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Korea.
J Cell Mol Med. 2014 May;18(5):875-84. doi: 10.1111/jcmm.12235. Epub 2014 Feb 18.
Retinal neovascularization in retinopathy of prematurity (ROP) is the most common cause of blindness for children. Despite evidence that hypoxia inducible factor (HIF)-1α -VEGF axis is associated with the pathogenesis of ROP, the inhibitors of HIF-1α have not been established as a therapeutic target in the control of ROP pathophysiology. We investigated the hypothesis that degradation of HIF-1α as a master regulator of angiogenesis in hypoxic condition, using β-lapachone, would confer protection against hypoxia-induced retinopathy without affecting physiological vascular development in mice with oxygen-induced retinopathy (OIR), an animal model of ROP. The effects of β-lapachone were examined after intraocular injection in mice with OIR. Intraocular administration of β-lapachone resulted in significant reduction in hypoxia-induced retinal neovascularization without retinal toxicity or perturbation of developmental retinal angiogenesis. Our results demonstrate that HIF-1α-mediated VEGF expression in OIR is associated with pathological neovascularization, not physiological angiogenesis. Thus, strategies blocking HIF-1α in the developing eye in the pathological hypoxia could serve as a novel therapeutic target for ROP.
早产儿视网膜病变(ROP)中的视网膜新生血管形成是儿童失明的最常见原因。尽管有证据表明缺氧诱导因子(HIF)-1α-血管内皮生长因子(VEGF)轴与ROP的发病机制有关,但HIF-1α抑制剂尚未被确立为控制ROP病理生理学的治疗靶点。我们研究了这样一个假设,即使用β-拉帕醌在缺氧条件下降解作为血管生成主要调节因子的HIF-1α,将在氧诱导性视网膜病变(OIR)小鼠(ROP的一种动物模型)中预防缺氧诱导的视网膜病变,同时不影响生理性血管发育。在OIR小鼠眼内注射后检测β-拉帕醌的作用。眼内给予β-拉帕醌可显著减少缺氧诱导的视网膜新生血管形成,且无视网膜毒性或对发育性视网膜血管生成的干扰。我们的结果表明,OIR中HIF-1α介导的VEGF表达与病理性新生血管形成有关,而非生理性血管生成。因此,在病理性缺氧的发育眼中阻断HIF-1α的策略可作为ROP的一种新型治疗靶点。